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Introduction
Within the realms of noncommunicable disease 
development in South Africa, obesity is a disease that 
causes concern. This especially holds true for type 2 
diabetes and cardiovascular diseases. Disheartened 
obese individuals who are unsuccessful with weight 
management might consider anti-obesity treatment, 
such as leptin. In this review paper, we will attempt to 
describe the adipocytokine, leptin, and especially its 
actions on the cardiovascular system.
The discovery of leptin
Leptin, which is a 16 kDa hormone, was first identified 
in 1994.1,2 What made this discovery significant was 
that leptin is mainly synthesised and secreted by 
subcutaneous white adipose cells. This gave rise to 
the notion that adipose tissue is an endocrine organ. 
Since leptin is mainly secreted by adipose tissue, serum 
leptin levels are directly proportional to adipocyte 
mass.3-5 Leptin has a central role in energy homeostasis.6 
It stimulates energy expenditure and inhibits appetite 
via the hypothalamus.7,8  Originally, these were the 
properties that raised the hopes of the public and 
industry that it might play a possible role in weight loss 
therapy.
Leptin and obesity
The importance of leptin in regulating the appetite 
and in energy expenditure was clearly demonstrated 
by individuals with congenital leptin deficiency who 
expressed severe hyperphagia (from the age of four 
months) and subsequent obesity.9,10 Within these 
severely obese individuals, hormone replacement 
therapy represented the first, rationally based 
and effective treatment of human obesity.11 The 
treatment consisted of daily subcutaneous injections 
of recombinant human leptin, and was expected to 
have beneficial effects on appetite, adipose mass 
and hyperinsulinaemia.12 However, congenital leptin 
deficiency is a rare human genetic syndrome.13 
Today, the obese population is not characterised by 
leptin deficiency, but is hyperleptinaemic, which is 
indicative of a leptin-resistant state.7 These elevated 
circulating leptin concentrations clearly fail to return 
body adiposity to within the lean range.14 Therefore, 
the ability of exogenous leptin to reduce food intake 
and body weight in the face of replete adipose stores 
(especially in obese individuals), seemed to be even 
more limited.15 Exogenous leptin doses produce a 
circulating leptin level more than 10 times that of 
normal levels, and result in only a small mean decrease 
in the body weight of obese subjects.16 
The poor efficacy of leptin to promote leanness in 
obese individuals and the hyperleptinaemic state of 
obese subjects gave rise to the notion of functional 
leptin resistance. This term is loosely based on and 
comparable with the concept of insulin resistance 
in type 2 diabetes.14 It is of utmost importance to 
understand the possible mechanisms behind leptin 
resistance in order to determine the causes of obesity 
and to identify potential mechanisms that could be 
targeted for therapy.
The more effective role of exogenous leptin admin-
istration was demonstrated, which was based on 
results that indicated a relative leptin deficiency in 
the post-obese state.7,17,18 After weight loss, obese 
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individuals indicated a steep decrease in serum leptin 
that was disproportional to changes in adiposity.7 This 
resulted in an increased appetite and decreased 
energy expenditure, with consequential weight gain. 
More recently, it was shown that exogenous leptin 
administration in weight-reduced obese subjects 
resulted in improved satiation.19 
To summarise, the existing evidence on recombinant 
leptin therapy suggests that relatively high doses 
of exogenous leptin result in only a small decrease 
in the body weight of obese individuals.14-16,20 This 
is understandable in the case of a leptin-resistant 
condition in obese individuals.
The metabolic functions of leptin 
It is not the main purpose of this paper to unravel the 
metabolic effects of leptin, which are quite wide-
ranging. In short, leptin is an important regulator 
of insulin action. This is demonstrated by leptin-
deficient and leptin-resistant conditions, which 
are both characterised by insulin-resistant glucose 
metabolism.21,22 Also, in subjects with leptin deficiency, 
leptin administration improves insulin sensitivity.6 Insulin, 
in turn, stimulates leptin secretion by adipocytes.23 This 
so-called adipoinsular axis functions as a hormonal 
regulatory feedback loop under normal physiological 
conditions.24-26 The physiological regulation of body 
weight by leptin seems to be disturbed (leptin 
resistance) in overweight or obese individuals. At the 
level of the pancreatic β-cell, leptin resistance may 
contribute to dysregulation of the adipoinsular axis 
and result in hyperinsulinemia, and ultimately the 
development of type 2 diabetes mellitus.27 
Apart from its effects on insulin, leptin seems to have 
various beneficial effects under normoglycaemic 
conditions, including hepatic glucose production and 
lipid metabolism.14 However, under hyperleptinaemic 
or hyperglycaemic conditions, these functions are 
disrupted, as in the obese leptin-resistant state.14
The biological functions of leptin are far-reaching, 
and even include providing support to reproductive 
competence, immune function and bone biology.14,28-30 
Leptin and the cardiovascular system
Apart from the central functions that involve energy 
metabolism and homeostasis, leptin may also exert 
actions that relate to cardiovascular homeostasis 
directly.
The actions within the cardiovascular system to 
maintain normal blood pressure seem to be balanced 
(Figure 1) in lean individuals with normoglycaemia and 
leptin sensitivity. These actions refer to blood pressure-
lowering mechanisms (via vasodilation, by promoting 
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Studies demonstrate that hyperleptinaemia predicts 
acute cardiovascular events48 and mortality,1,43
independent of traditional risk factors
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Figure 1: The cardiovascular actions of leptin
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nitric oxide release from the endothelium),4,5,31 but 
also to mechanisms that increase blood pressure. 
These pressor actions mainly refer to the elevating 
sympathetic drive32-34 via the corticotrophin-releasing 
factor.35 Elevated renal sympathetic nerve activity 
results in sodium retention, volume expansion, and 
blood pressure elevation.36 Leptin also promotes 
the release of vasoconstrictive substances, such as 
angiotensin II and endothlin-1,24,37,38 thereby increasing 
blood pressure.
However, in obese hyperleptinaemic or leptin-
resistant conditions, the homeostatic control of blood 
pressure is impaired. Although leptin resistance refers 
to the condition of diminished cellular and metabolic 
responsiveness to leptin,14 a condition of partial or 
selective leptin resistance seems to exist. Selective 
resistance is thought to occur mainly in central 
neural signalling pathways downstream of the leptin 
receptor.22,44 Thus, the metabolic effects of leptin, which 
result from the arcuate nucleus, are impaired, whereas 
the sympathoexcitatory effects are maintained.45 
This limits the effectiveness of leptin in the treatment 
of common human obesity.46 Consequently, much 
research has been devoted to finding the mechanisms 
and treatment of partial leptin resistance in human 
obesity.22,44 
Apart from its described pressor and depressor actions, 
leptin also affects atherogenesis,24,39,42 angiogenesis8 
and thrombosis,47 via direct and indirect mechanisms. 
At the vascular level, leptin seems to potentiate the 
secretion of various inflammatory markers (C-reactive 
protein, tumour necrosis factor and interleukin 2 and 
6),1 and stimulates the migration and proliferation 
of smooth muscle cells.48 In obese conditions, lep-
tin may also increase oxidative stress though multiple 
mechanisms.40,41 
When taking these wide-ranging cardiovascular ac-
tions of leptin into consideration, it is no wonder that 
numerous clinical studies have shown that hyper- 
leptinaemia predicts acute cardiovascular events and 
restenosis after coronary injury and cerebral stroke, 
independent of traditional risk factors.43,47,49
The role of ethnicity and gender on the 
cardiovascular effects of leptin
Healthy women have substantially higher leptin levels 
than men.24 This was also demonstrated in black and 
white South African populations.50 With regards to 
gender, it is unclear what the underlying mechanisms 
are. They may be due to differential fat distribution or 
different gender-related hormonal influences.51,52 Clear 
ethnic differences, with regard to the concentrations, 
as well as their association with cardiovascular 
measurements, were also described in the South 
African context (Figure 2). Our group and others have 
found that lean and overweight black women have 
higher serum leptin concentrations than age- and 
obesity-matched white women.53,54 These higher leptin 
levels were accompanied by elevated blood pressure. 
However, when a comparison was made between 
obese black and white women, leptin levels were 
similar.55 In addition to the ethnic differential leptin 
levels in pre-obese conditions, we also observed much 
stronger associations between leptin and various areas 
of fat deposition, namely body fat percentage, waist 
circumference, and skin-fold thicknesses of the iliac 
crest.56 Thus, although black women exhibit higher leptin 
levels, their leptin concentrations are more weakly 
associated with obesity indices than those of white 
women. It is challenging to explain this observation, but 
it may be possible that certain tissues of black women, 
such as the stomach, ovaries, or skeletal muscle, may 
be more active in producing leptin independently of 
adipose tissue.57
When investigating the links of leptin with blood 
pressure in obese women, we found that leptin in 
obese hypertensive black women is associated with 
systolic blood pressure and low arterial compliance. 
This was not evident in obese, but normotensive 
black women.61 Contrarily, obese white women who 
had similar leptin levels to obese African women had 
favourable associations of leptin with cardiovascular 
function.53 This ethnic discrepancy is difficult to explain, 
but indicates an ethnic vulnerability which should be 
noted.
Cardiac changes are also a well-known consequence 
of obesity-related hypertension. Norton et al have 
described that adiposity-induced increases in left 
ventricular mass reflected an enhanced effect of 
blood pressure on left ventricular growth, which is an 
effect that may be mediated by leptin.56
With regard to cardiometabolic consequences, we 
found that elevated leptin concentrations in both 
black and white women increased their odds of having 
the metabolic syndrome by six- to eightfold.10,64 Based 
on the various actions of leptin discussed before, this 
elevated risk could be explained by the detrimental 
effects of obesity, but also by the various metabolic 
and cardiovascular effects of hyperleptinaemia.
Apart from the link between leptin and blood pressure, 
we investigated whether leptin is also associated with 
subclinical atherosclerosis in black and white school 
teachers. Surprisingly, we found a significant and 
independent association between leptin and carotid 
cross-sectional wall area, which was independent of 
obesity, ethnicity and gender. This provides evidence 
of the atherogenic effects of leptin beyond blood 
pressure.50
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On the other side of the obesity spectrum, it is well-
known that a U-shaped curve exists between body 
mass index and mortality.62 We found supporting 
evidence for this phenomenon in underweight (human 
immunodeficiency virus-uninfected) black men who 
exhibited strong positive relationships between blood 
pressure and leptin levels.58 Since hypertension is not 
uncommon in lean and underweight black men, this 
finding may add mechanistic support to understand 
this phenomenon.
Conclusion
Consideration should be given to leptin and its significant 
actions, particularly within the cardiovascular system. 
Since the net effects of leptin on cardiovascular 
pathophysiology remain complex and are not clearly 
understood, careful evidence-based decisions 
should be made when considering exogenous leptin 
administration. 
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